Form 4: MapLight CFO Executes Planned Stock Sale

MapLight Therapeutics CFO Vishwas Setia sold 36,371 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Vishwas Setia, Chief Financial Officer of MapLight Therapeutics, sold a total of 36,371 shares of voting common stock.
• The transactions occurred between May 4, 2026, and May 6, 2026.
• The sales were executed at weighted average prices ranging from $27.36 to $30.12 per share.
• Following these transactions, the reporting person retains ownership of 356,256 shares of common stock.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions were pre-planned and do not indicate a change in the company's fundamental outlook or management's confidence.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the equity stake held by a key executive, specifically the Chief Financial Officer.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future growth prospects.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice. While it reduces the executive's direct exposure to the stock, it is generally viewed as a neutral event when conducted under a pre-planned schedule, as it removes the element of discretionary timing based on market conditions.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while maintaining compliance with SEC regulations.
• The volume of shares sold relative to the remaining holdings is consistent with typical executive diversification strategies.

Stakeholder Impact

• Shareholders should note the reduction in the CFO's equity position, though the pre-planned nature of the sale mitigates concerns regarding insider sentiment.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, CFO, Rule 10b5-1